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Abstract
 
By stimulating human CD8
 

 
 T lymphocytes with autologous dendritic cells infected with an
adenovirus encoding MAGE-3, we obtained a cytotoxic T lymphocyte (CTL) clone that recog-
nized a new MAGE-3 antigenic peptide, AELVHFLLL, which is presented by HLA-B40. This
peptide is also encoded by 
 
MAGE-12
 
. The CTL clone recognized MAGE-3–expressing tumor
 
cells only when they were first treated with IFN-
 

 
. Since this treatment is known to induce the
exchange of the three catalytic subunits of the proteasome to form the immunoproteasome, this
result suggested that the processing of this MAGE-3 peptide required the immunoproteasome.
Transfection experiments showed that the substitution of 
 

 
5i (LMP7) for 
 

 
5 is necessary and
 
sufficient for producing the peptide, whereas a mutated form of 
 

 
5i (LMP7) lacking the cat-
alytically active site was ineffective. Mass spectrometric analyses of in vitro digestions of a
long precursor peptide with either proteasome type showed that the immunoproteasome pro-
duced the antigenic peptide more efficiently, whereas the standard proteasome more efficiently
introduced cleavages destroying the antigenic peptide. This is the first example of a tumor-spe-
cific antigen exclusively presented by tumor cells expressing the immunoproteasome.
Key words:
 

 
5i • proteasome • mass spectrometry • tumor • HLA-B40
 
Introduction
 
Therapeutic vaccinations of cancer patients aim at stimulat-
ing the immune system, in particular the CTL, so as to
eliminate cancer cells efficiently and safely (1). Various im-
munization modalities are being applied in vaccination trials:
injection of antigenic peptides, either alone or loaded onto
dendritic cells, injection of recombinant proteins or recom-
binant viral vectors encoding either the full-length protein
or only a single peptide. The dendritic cells most probably
play a crucial role in the activation of the CTL precursors,
and they have to present efficiently the antigenic peptides at
their surface. Once activated, the CTLs have to reach the
tumor site and destroy the tumor cells expressing the same
antigenic peptides. Such peptides are presented by MHC
class I molecules, and derive from intracellular proteins that
are degraded by the proteasome, a proteolytic complex
playing a critical role in this antigen processing pathway.
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The catalytic core of the standard proteasome has the
shape of a barrel made of four rings, with the three catalyt-
ically active subunits, 
 

 
1, 
 

 
2, and 
 

 
5 located in each of the
two inner rings (2). It was recently shown that mature den-
dritic cells express a different sort of proteasome in which
the three catalytic subunits are replaced by their IFN-
 

 
–
inducible homologs, 
 

 
1i (LMP2), 
 

 
2i (MECL1), and 
 

 
5i
(LMP7) (3, 4). The resulting proteasome, named immuno-
proteasome, has slightly different catalytic activities, which
can result in different cleavage specificities (5–7). There-
fore, a number of antigenic peptides are not processed with
the same efficiency by the immunoproteasome and by the
standard proteasome (8). Most nonlymphoid cells, be they
normal or tumoral, constitutively express standard protea-
somes, and switch to immunoproteasomes when exposed
to IFN-
 

 
 (2).
Since mature dendritic cells and cancer cells constitu-
tively express different proteasome types, it is crucial for the
success of cancer immunotherapy to determine precisely
the relative efficiency of the two proteasome types to pro-
cess the antigenic peptides considered. For viral antigens,
there are several examples of peptides that are processed ex-
clusively by the immunoproteasome (9–11). On the oppo-
site, some antigenic peptides derived from self-proteins ex-
pressed either ubiquitously or only in the melanocytic
lineage appear to be processed more efficiently by the stan-
dard proteasome (4, 8).
We report here the characterization of a new tumor-spe-
cific peptide which is recognized by CTLs exclusively on
melanoma cells expressing the immunoproteasome. This
antigenic peptide is encoded by genes 
 
MAGE-3
 
 and
 
MAGE-12
 
. These genes are expressed in various tumors
but not in most normal tissues and they encode several tu-
mor-specific antigens recognized by T lymphocytes (12).
The new MAGE-3 antigen described here was identified in
the course of an effort to identify additional tumor-specific
peptides of clinical interest.
 
Materials and Methods
 
Cell Lines, Media, Reagents, and Antibodies.
 
The Epstein-Barr
virus–immortalized B (EBV-B)
 
*
 
 cell lines and the melanoma cell
lines were cultured in IMDM supplemented with 10% FCS.
COS-7 cells were maintained in DMEM medium supplemented
with 10% FCS. All culture media were purchased from Life
Technologies and supplemented with 0.24 mM 
 
L
 
-asparagine,
0.55 mM 
 
L
 
-arginine, 1.5 mM 
 
L
 
-glutamine (AAG), 100 U/ml
penicillin, and 100 
 

 
g/ml streptomycin. Human recombinant
IL-2 was purchased from Eurocetus. 1 U/ml of IL-2 is the con-
centration needed to obtain half-maximal proliferation of mouse
CTLL-2 cells. IL-7 was purchased from Genzyme, GM-CSF
(LEUCOMAX) from Novartis Pharma, and IFN-
 

 
 from R&D
Systems. Human recombinant IL-4, IL-6, and IL-12 were pro-
duced in our laboratory. 1 U/ml of IL-6 is the concentration
needed to obtain half-maximal proliferation of mouse 7TD1
 
cells (13). Flow-cytometric analyses were performed with the
following antibodies: CD3-FITC, CD4-FITC, and CD8-FITC
(Becton Dickinson).
 
Recombinant Viruses.
 
The vaccinia virus encoding MAGE-3
(vaccinia MAGE-3) was provided by Vincenzo Cerundolo (Mo-
lecular Immunology Group, University of Oxford, UK). Before
infection, the vaccinia virus samples were sonicated for 30 s. For
the construction of the recombinant adenovirus adeno-MAGE-3,
the plasmid pAd-CMVIcpA-MAGE-3, containing the 
 
MAGE-3
 
cDNA under the control of the cytomegalovirus promoter, was
obtained by inserting the complete 
 
MAGE-3
 
 cDNA into the
NotI site of vector pAd-CMVIcpA (provided by Celia Garcia
and Thierry Ragot, Institut Gustave Roussy, Paris, France). The
recombinant adeno-MAGE-3 was constructed in cell line 293 by
in vivo homologous recombination between pAd-CMVIcpA-
MAGE-3 and adeno-
 

 
gal genomic DNA (14). The recombinant
adenovirus was plaque purified, propagated in 293 cells, and puri-
fied by double cesium chloride density centrifugation. The con-
struction of the retroviral construct coding for MAGE-3 and the
transfection of cell lines was done as described previously (15).
 
Dendritic Cells and CD8
 

 
 Responder T Cells.
 
Peripheral blood
was obtained from hemochromatosis patient LB1841 as standard
buffy coat preparations, which were laid down on a 15-ml Lym-
phoprep layer (Nycomed Pharma) in 50-ml tubes. To minimize
contamination of the PBMCs by platelets, the tubes were first
centrifuged at 1,000 rpm for 20 min at room temperature. After
removal of the top 20–25 ml, containing most of the platelets, the
tubes were centrifuged at 1,500 rpm for 20 min at room temper-
ature. The interphase containing the PBMCs was harvested and
washed three times (or more) in cold phosphate buffer solution
with 2 mM EDTA in order to eliminate the remaining platelets.
To generate autologous dendritic cells, PBMCs were depleted
from T lymphocytes by rosetting with sheep erythrocytes (Bio
Mérieux) treated with 2-aminoethylisothiouronium (Sigma-
Aldrich). Rosetted T cells were treated with NH
 
4
 
CL (160 mM)
to lyse the sheep erythrocytes and washed. CD8
 

 
 T lymphocytes
were isolated from rosetted T cells by positive selection using an
anti-CD8 mAb coupled to magnetic microbeads (Miltenyi Bio-
tec). They were then sorted through a magnet and subsequently
frozen. The day before the first stimulation, CD8
 

 
 T cells were
thawed and grown overnight in IMDM supplemented with 10%
human serum, AAG, and antibiotics (hereafter referred to as
complete IMDM) in the presence of 10 U/ml of IL-2. The lym-
phocyte-depleted PBMCs were left to adhere for 2 h at 37
 

 
C in
culture flasks (FALCON; Becton Dickinson) at a density of 10
 
6
 
 cells
per cm
 
2
 
 in RPMI 1640 supplemented with Hepes (2.38 g/liter),
AAG, antibiotics, and 10% FCS (hereafter referred to as complete
RPMI medium). Nonadherent cells were discarded and adherent
cells were cultured in the presence of IL-4 (100 U/ml) and GM-
CSF (100 ng/ml) in complete RPMI medium. Cultures were fed
on days 2 and 4 by removing 1/3 of the volume and adding fresh
medium with IL-4 (100 U/ml) and GM-CSF (100 ng/ml). On
day 7, 
 

 
95% of the cells were CD14
 

 
CD83
 

 
CD86
 
lo
 
HLA-DR
 
lo
 
as assessed by flow cytometry (FACScan™; Becton Dickinson)
after labeling with CD14-FITC, CD83-PE, CD86-PE, or HLA-
DRPE (Becton Dickinson). They were frozen on day 7.
 
Mixed Lymphocyte–Dendritic Cells Culture.
 
Autologous den-
dritic cells from donor LB1841 (2 
 
	
 
 10
 
6
 
) were thawed and in-
fected with the adeno-MAGE-3 virus, at a multiplicity of infec-
tion of 500, in 200 
 

 
l of complete RPMI medium at 37
 

 
C under
5% CO
 
2
 
. The infected dendritic cells were washed after 2 h. Au-
tologous responder CD8
 

 
 T lymphocytes (150,000) and infected
dendritic cells (30,000) were cocultured in U-bottomed micro-
 
*
 
Abbreviation used in this paper:
 
 EBV-B cell, Epstein-Barr virus–immortal-
ized B cell.
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wells in 200 
 

 
l of complete IMDM in the presence of IL-6 (1,000
U/ml) and IL-12 (10 ng/ml). The CD8
 

 
 lymphocytes were
stimulated once per week with autologous dendritic cells freshly
infected with the adeno-MAGE-3 virus, and grown in complete
IMDM supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml).
 
Cytotoxicity Assay.
 
To test the MAGE-3 reactivity of the mi-
crocultures, autologous EBV-B cells were infected for 2 h with
either the parental vaccinia virus or the vaccinia MAGE-3 con-
struct using a multiplicity of infection of 20. The infected target
cells were then labeled with 100 
 

 
Ci of Na(
 
51
 
Cr)O
 
4
 
 for 1 h,
washed, and added to the responder cells. Unlabeled K562 cells
were also added (5 
 
	
 
 10
 
4
 
 per V-bottomed microwell) to block
natural killer activity. The individual microcultures were tested in
duplicate on each target at an effector/target ratio of 
 

 
40:1.
Chromium release was measured after incubation at 37
 

 
C for 4 h.
To test the lytic activity of CTL 52, no unlabeled K562 cells were
added during the assay. The melanoma cell lines were treated or
not with 100 U/ml of IFN-
 

 
 for 48 h and labeled with
Na(
 
51
 
Cr)O
 
4
 
 as described above.
 
Isolation of CTL Clones Specific for MAGE-3.
 
1 microculture
containing cells with anti–MAGE-3 reactivity was cloned by lim-
iting dilution in 96-well plates using irradiated autologous
EBV-B cells transduced with a retrovirus coding for MAGE-3 as
stimulating cells (5,000–15,000 cells per well), and irradiated allo-
geneic LG2-EBV as feeder cells (5,000–15,000 cells per well), in
the presence of IL-2 (50 U/ml). CTL clones were maintained in
culture in 24-well plates by weekly restimulation with either au-
tologous EBV-B cells transduced with a retrovirus coding for
MAGE-3 (10
 
5
 
 cells) or purified PHA (0.5 
 

 
g/ml) (HA 16;
Murex Biotech) in complete IMDM supplemented with 50
U/ml IL-2, in the presence of allogeneic LG2-EBV as feeder cells
(10
 
6
 
 cells).
 
Transfection of COS-7 Cells and TNF Assay.
 
COS-7 cells (1.5 
 
	
 
10
 
4
 
) were distributed in microwells and cotransfected using 1 
 

 
l
of LIPOFECTAMINE (Life Technologies) with the indicated
cDNAs cloned into expression plasmids that multiply episomally
in COS-7 cells (16). The 
 
MAGE-1
 
, 
 
3
 
, 
 
4
 
, 
 
8
 
, 
 
9
 
, 
 
10
 
, 
 
11
 
, and 
 
12
 
cDNAs were inserted into pcDNAI/Amp (Invitrogen). The
 
MAGE-2
 
 and 
 
6
 
 cDNAs were inserted into pcDSR-
 


 
 (17). The
 
HLA-B
 
*
 
4001
 
 cDNA was inserted into pcDNA3 (Invitrogen).
The HLA coding sequences were isolated from various individu-
als and were also inserted into pcDNA3. The COS-7 cells were
incubated for 24 h at 37
 

 
C and 8% CO
 
2
 
. Transfectants were
tested for their ability to stimulate the production of TNF by
CTL 52. Briefly, 2,500 CTLs were added to the transfectants, in a
total volume of 100 
 

 
l of complete IMDM containing 25 U/ml
of IL-2. After 24 h, the supernatant was collected and its TNF
content was determined by testing its cytotoxic effect on WEHI-
164 clone 13 cells in a MTT colorimetric assay (18–20).
 
Site-directed Mutagenesis of 
 

 
5i.
 
In vitro–directed mutagenesis
was performed on the 
 

 
5i cDNA cloned into vector pEF-
BOSpuro (PL3) with the Gene editor in vitro site–directed mu-
tagenesis kit (Promega) using the mutagenesis primer 5
 

 
-P-GC-
CCATGGCGCCACCACGCTC-3
 

 
 and the top strand selection
primer. The mutation (G instead of A) introduced in the primer
changes a Threonine into an Alanine at position 73 of the full-
length 
 

 
5i.E2 protein (i.e., position 1 of the mature protein)
(21, 22).
 
Transfection of 293-EBNA Cells and IFN-
 

 
 Assay.
 
Human
293-EBNA cells (15,000) were transiently transfected in micro-
wells with 150 ng of cDNA and 1.3 
 

 
l of LIPOFECTAMINE.
 

 
1i was cloned in expression vector pcDNA3 (Invitrogen), 
 

 
2i in
pEF/myc/cyto (Invitrogen), 
 

 
5i, and mutated 
 

 
5i in pEF-
 
BOSpuro (PL3) (4, 23). cDNAs coding for MAGE-3, HLA-
B
 
*
 
4001, 
 

 
1i, 
 

 
2i, 
 

 
5i, or mutated 
 

 
5i were added in different
combinations in the DNA mix at 30 ng each, and 
 

 
 galactosidase
(
 

 
 Gal) was added to reach a total of 150 ng. 2 d after transfec-
tion, 7,000 cells of CTL 52 were added to the transfected cells.
IFN-
 

 
 production was measured by ELISA after 20 h of cocul-
ture. SK28-MEL were treated with IFN-
 

 
 (100 UI/ml) for 48 h
where indicated.
 
Determination of the Antigenic Peptide.
 
Peptides were synthe-
sized on solid phase using F-moc for transient NH
 
2
 
-terminal pro-
tection and were characterized using mass spectrometry. All
peptides were 
 

 
90% pure, as indicated by analytical HPLC. Ly-
ophilized peptides were dissolved at 2 mg/ml in 10 mM acetic
acid and 10% DMSO, and stored at –20
 

 
C. The first screening
was performed with autologous EBV-B cells incubated with pep-
tides at a concentration of 1 
 

 
g/ml, and tested for recognition by
CTL 52 at an effector/target ratio of 5:1.
 
Purification and Quantification of 20S Proteasomes.
 
Frozen pel-
lets of LB1751 cells and of LB1751 cells treated with IFN-
 

 
 for
10 d (100 U/ml) were lysed on ice in Tris 25 mM NaCl 50 mM,
pH 
 
 
 
7.5, and homogenized in a Dounce homogenizer. Unsolu-
bilized material was removed by centrifugation at 40,000 
 
g
 
. Pro-
teasomes were purified from cleared supernatants by immuno-
affinity chromatography on MCP21 (a mAb directed against
subunit 
 


 
2, ECACC96030418) covalently linked to CNBr-acti-
vated 4B sepharose beads (Amersham Pharmacia Biotech) as de-
scribed previously (24). The purity of the proteasome was
checked by SDS-PAGE and was 
 

 
95%. Purified proteasomes
were quantified with a BCA Protein Assay (Pierce Chemical
Co.). A second quantification was performed by a sandwich
ELISA: 96-well microtiter plates (Nunc-Immuno Plate and Maxi-
Sorp; Life Technologies) were coated with the MCP-21 (5 
 

 
g/
ml) by overnight incubation at 4
 

 
C in 100 
 

 
l of PBS. Plates were
then washed three times with PBS containing 0.1% Tween 20
(PBS-T), blocked with PBS containing 2% BSA for 1 h at room
temperature, and washed again three times with PBS-T. 100 
 

 
l
of serial dilutions of purified proteasomes were added to the plates
and incubated for 2 h at room temperature. After this incubation
step, the plates were washed three times with PBS-T and incu-
bated with a rabbit antiserum (1 
 

 
g/ml) raised against human
proteasome for 1 h at room temperature. Subsequently, plates
were washed three times and incubated with 50 
 

 
l of AP-labeled
goat anti–rabbit (1:1,000) (Southern Biotechnology Associates)
for another 1 h at room temperature. Enzymatic reactions were
performed at room temperature by adding p-nitrophenyl phos-
phate (Sigma-Aldrich). Color development was measured at 405
nm in a microplate reader. Quantification of proteasomes was
performed in triplicates. Concentration was determined by re-
gression analysis based on a reference preparation of standard pro-
teasome from human erythrocytes.
 
Digestion of Synthetic Precursor Peptide and CTL Assay.
 
5 
 

 
g of
19-amino-acid-long precursor peptide LSRKVAELVHFLLL-
KYRAR were incubated with 4 
 

 
g of either standard or immu-
noproteasomes at 37
 

 
C in 86 
 

 
l of Tris buffer (25 mM, pH 7.6).
At different incubation times (0, 30, 60, 120 min), an aliquot (20
 

 
l) corresponding to the digestion of 1.25 
 

 
g precursor peptide
with 1 
 

 
g of proteasomes was removed from the digestion mix-
ture and the reaction stopped by addition of 2 
 

 
l of 10% trifluo-
roacetic acid. Aliquots were then lyophilized and stored at
 

 
20
 

 
C. Lyophilized digests were resuspended in 12 
 

 
l of cold
PBS. 5 
 

 
l were diluted to 155 
 

 
l in X-vivo 10 medium and 50
 

 
l of this dilution were pulsed in triplicates on 30,000 LB1841
EBV-B cells distributed in microculture plates. CTL 52 was
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added (6,000 cells per well) with IL-2 (25 U/ ml) in a final vol-
ume of 150 
 

 
l of X-vivo 10 medium. The supernatants were
collected after 20 h and their IFN-
 

 
 content was measured by
ELISA using reagents from Biosource.
 
Mass Spectrometry.
 
Digestions were performed with 20 
 

 
g of
the long precursor peptide and 4 
 

 
g of either standard or immu-
noproteasomes at 37
 

 
C in 86 
 

 
l of Tris buffer (25 mM, pH 7.6).
At different incubation times (0, 30, 60, 120 min), an aliquot (20
 

 
l) corresponding to the digestion of 5 
 

 
g precursor peptide with
1 
 

 
g of proteasomes was removed from the digestion mixture
and the reaction stopped by addition of 2 
 

 
l of 10% trifluoroace-
tic acid. Aliquots were then lyophilized and stored at
 
 
 
20
 

 
C.
Lyophilized digests were resuspended in 12 
 

 
l of cold PBS. 5 
 

 
l
were used for mass spectrometric analysis. Peptides were sepa-
rated on a Pepmap™ LC Packings C18 column (1 mm 
 
	
 
 10 cm)
at a flow rate of 40 
 

 
l/min. The separation was achieved with a
gradient elution of 5–55% B for 45 min (A is 5/95/0.05
CH3CN/H2O/HCOOH, B is 50/50/0.05 CH3CN/H2O/
HCOOH vol/vol/vol). Mass spectrometric analyses were per-
formed on a TSQ 700 triple quadrupole (Finnigan Mat)
equipped with an electrospray source. Mass spectra were obtained
by scanning the range of masses corresponding to 
 
m/z
 
 between
200 and 1,950 every 3 s. Peptide quantitation was obtained from
the peak height of a given mass/charge ratio in Reconstructed
Ion Current analysis, using an internal calibrating peptide. Results
are reported as relative intensities, corresponding to the measured
intensity of each fragment corrected for the measured intensity of
the precursor peptide at 
 
t
 
 
 

 
 0.
Results
 
Dendritic cells obtained from donor LB1841 were in-
fected with a recombinant adenovirus containing the entire
MAGE-3 coding sequence (adeno-MAGE-3). 96 micro-
cultures were set up with 3 
 
	
 
 10
 
4
 
 of these stimulator den-
dritic cells and 1.5 
 
	
 
 10
 
5
 
 autologous CD8
 

 
 T cells, in the
presence of IL-6 and IL-12. The T cells were restimulated
 
weekly with autologous dendritic cells infected with ad-
eno-MAGE-3, in the presence of IL-2 and IL-7. They
were tested on day 28 for their lytic activity on autologous
EBV-B cells infected with a vaccinia virus encoding
MAGE-3 (vaccinia-MAGE-3). A vaccinia recombinant vi-
rus was used to avoid detecting CTLs directed against ade-
noviral antigens. As a negative control, we used EBV-B
cells infected with the parental vaccinia virus.
5 microcultures displaying anti–MAGE-3 reactivity were
obtained. Microculture F7 was cloned by limiting dilution
in the presence of IL-2, irradiated allogeneic EBV-B cells as
feeder cells and irradiated autologous EBV-B cells trans-
duced with a retrovirus coding for MAGE-3 as stimulator
cells. Several CTL clones displaying anti-MAGE-3 reactiv-
ity were isolated, such as CTL clone LB 1841 526/F7.52
hereafter referred to as CTL 52. This CD3
 

 
 CD8
 

 
 CD4
 

 
clone lysed autologous EBV-B cells infected with vaccinia-
MAGE-3 but neither EBV-B cells infected with the paren-
tal vaccinia virus nor K562 cells (Fig. 1).
 
A New MAGE-3 Antigenic Peptide Presented by HLA-
B
 
*
 
4001.
 
Donor LB1841 was serologically typed HLA-
A3, B35, B60, Cw3, and Cw4. Genetic typing for the
HLA-B loci revealed that B60 corresponds to B
 
*
 
4001. To
identify the HLA molecule that presents the MAGE-3 pep-
tide recognized by CTL 52, COS-7 cells were transiently
transfected with the 
 
MAGE-3
 
 cDNA together with each of
the cDNAs encoding these HLA molecules. Transfected
cells were subsequently tested for recognition by CTL 52.
Only these cells that were transfected with both 
 
MAGE-3
 
and 
 
HLA-B
 
*
 
4001
 
 stimulated CTL 52 to produce TNF
above the level obtained by transfecting only 
 
MAGE-3
 
(Fig. 2).
Figure 1. Lysis by CTL 52 of autologous EBV-B cells infected with
vaccinia-MAGE-3. LB1841-EBV-B cells were infected for 2 h with ei-
ther vaccinia-MAGE-3 or parental vaccinia at a multiplicity of infection
of 20. The infected EBV-B cells and K 562 cells were 51Cr-labeled for
1 h, and incubated with the CTL clone at the indicated effector-to-target
ratios. Chromium release was measured after 4 h.
Figure 2. The MAGE-3 antigenic peptide is presented by HLA-B40
molecules. Monkey COS-7 cells were transiently transfected with a
MAGE-3 cDNA and each of the cDNAs coding for putative HLA-pre-
senting molecules. Transfections were performed in microwells with
15,000 COS-7 cells, 50 ng of each cDNA and 1 l of LIPO-
FECTAMINE. 1 d after transfection, 2,500 cells of CTL 52 were added
to the transfected cells. TNF production was measured after overnight
coculture by testing the toxicity of the supernatants for TNF-sensitive
WEHI-164 clone 13 cells.
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To determine whether the peptide recognized by CTL
52 is also encoded by other MAGE genes, COS-7 cells
were transiently transfected with an HLA-B*4001 cDNA
together with cDNAs corresponding to other genes of the
MAGE-A family that are expressed in tumors (25). We ob-
served that cells transfected with MAGE-12 were also rec-
ognized by CTL 52 (Fig. 3).
Identification of the Antigenic Peptide. To identify the an-
tigenic peptide recognized by CTL 52 on HLA-B40 mole-
cules, a set of MAGE-3 peptides was screened. These 16
amino-acid long peptides overlapped by 12 residues and
covered the entire MAGE-3 protein sequence. Autologous
EBV-B cells were incubated with each of these peptides at
a concentration of 1 g/ml and tested for lysis by CTL 52.
36% of lysis was observed with cells pulsed with peptide
AALSRKVAELVHFLLL compared with 7% using the
other peptides. Nonapeptide AELVHFLLL (MAGE-3114–122
and MAGE-12114–122), which corresponds to the COOH-
terminal part of this peptide, contains the consensus anchor
motif for HLA-B40 (B60), namely E in position 2 and L in
position 9 (26). It produced half-maximal lysis of the pulsed
target cells at a concentration of 1 nM (Fig. 4). Octapep-
tide AELVHFLL was not recognized by the CTL (data not
shown).
Lysis of HLA-B40-positive Tumor Cell Lines Expressing
MAGE-3. 3 melanoma cell lines that were obtained from
HLA-B40 patients and that expressed MAGE-3 were
tested for their recognition by CTL 52 in a chromium re-
lease assay. None of them was lysed. However, all these
cells were lysed after treatment with IFN- during 48 h be-
fore the test (Fig. 5). The three melanoma lines were well
recognized, even in the absence of IFN- treatment, when
they were pulsed with peptide AELVHFLLL, indicating
that HLA-B40 molecules were present and that the effect
of IFN- did not simply result from their induction. We
also observed that the IFN- treatment did not increase the
level of expression of MAGE-3, as measured by semiquan-
titative RT-PCR (data not shown).
The Production of the MAGE-3 Antigenic Peptide Requires
the Immunoproteasomes. The effect of IFN- on the recog-
nition of the B40 cell lines suggested that the immunopro-
teasome was required for the production of the MAGE-
3.B40 antigen. To prove this, we transfected 293-EBNA
cells with low amounts of MAGE-3 and HLA-B40 cDNAs,
together with the cDNAs coding for immunoproteasome
subunits 1i, 2i, and 5i. In the absence of those sub-
units, there was no recognition of the transfected cells by
CTL 52. The cotransfection of 5i was sufficient to allow
recognition of the transfected cells, whereas the transfec-
tion of 1i and 2i had no effect (Fig. 6). Transfection of
the three immunoproteasome subunits together did not re-
sult in a better recognition of the cells than transfection of
5i alone. Cells transfected with a mutated form of 5i
lacking the threonine of the catalytic site were unable to
activate CTL 52, indicating that the catalytic activity of 5i
is required for the production of the antigenic peptide.
To study further the mechanisms leading to the differ-
ence in the production of the antigenic peptide by the two
types of proteasome, we compared the results of the diges-
tion of a long precursor peptide by either immunoprotea-
somes or standard proteasomes, which were purified from
melanoma cells treated or not with IFN-, respectively.
The presence of subunits 1i, 2i, and 5i in the immuno-
proteasome preparation and their almost complete absence
in the standard proteasome batch were confirmed by im-
Figure 3. The peptide recognized by CTL 52 is encoded by MAGE-3
and MAGE-12. Monkey COS-7 cells were transiently transfected with
an HLA-B*4001 cDNA and each of the MAGE-A cDNAs. Transfections
were performed in microwells with 15,000 COS-7 cells, 50 ng of each
cDNA and 1 l of LIPOFECTAMINE. 1 d after transfection, 2,000 cells
of CTL 52 were added to the transfected cells. TNF production was mea-
sured after overnight coculture by testing the toxicity of the supernatants
for TNF-sensitive WEHI-164 clone 13 cells.
Figure 4. Titration of peptide AELVHFLLL. LB1841-EBV-B cells
were 51Cr-labeled and incubated for 30 min with threefold dilutions of
the synthetic peptide. Autologous CTL 52 was subsequently added at an
effector/target ratio of 5:1. Chromium release was measured 4 h later.
The concentrations indicated in the figure correspond to the concentra-
tions during the 4-h incubation.
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munoblotting (data not shown). The precursor peptide was
19-residue long, corresponding to position 109–127 of
the MAGE-3 protein, encompassing antigenic peptide
114AELVHFLLL122 and its natural flanking residues. Digests
obtained after different incubation times were pulsed onto
HLA-B40-positive cells and tested for recognition by CTL
52. In accordance with our previous data, the digests ob-
tained with immunoproteasomes stimulated CTL 52 much
more efficiently than those obtained with standard protea-
somes (Fig. 7).
To understand why the processing of this peptide re-
quires the immunoproteasome, the proteasome-mediated
digests were analyzed by mass spectrometry. The cleavage
products obtained after digestion of 5 g of peptide were
separated by reverse-phase HPLC, identified, and quanti-
Figure 5. Lysis of tumor cell lines by CTL 52. MAGE-3–expressing melanoma cell lines SK28-MEL, LB43-MEL, CP50-MEL, and SK31-MEL were
treated or not with IFN- (100 U/ml) for 48 h and used as targets. Target cells were 51Cr-labeled for 1 h, and incubated with CTLs at various effector/tar-
get ratios. Chromium release was measured after 4 h. Lines SK28-MEL, LB43-MEL, and CP50-MEL were HLA-B*4001-positive, SK31-MEL was not.
Figure 6. Recognition by CTL 52 of cells transfected with cDNAs
coding for MAGE-3, HLA-B40, and the subunits of the immunoprotea-
some. Human 293-EBNA cells (15,000) were transiently transfected in
microwells with 150 ng of cDNA in the presence of 1.3 l of LIPO-
FECTAMINE. cDNAs coding for MAGE-3, HLA-B40, 1i, 2i, 5i,
or mutated 5i were added in different combinations in the DNA mix at
30 ng each, and cDNA coding for  galactosidase ( Gal) was added to
reach a total of 150 ng. 2 d after transfection, 7,000 cells of CTL 52 were
added to the transfected cells. IFN- production was measured by ELISA
after 20 h of coculture. The results shown represent the average and SD
of triplicate cocultures. SK28-MEL were treated with IFN- (100 UI/
ml) for 48 h where indicated.
Figure 7. Recognition by CTL 52 of peptide digests performed with
purified proteasomes. A 19 amino acid-long precursor peptide,
109LSRKVAELVHFLLLKYRAR127, encompassing antigenic peptide
114AELVHFLLL122, was digested in vitro with different proteasome prep-
arations. Immunoproteasomes were purified from LB1751-MEL mela-
noma cells treated for 10 d with IFN- (100 U/ml), and standard protea-
somes were obtained from untreated LB1751-MEL cells. Digestions were
performed with 1 g of proteasomes and 1.25 g of the precursor peptide.
One-seventh of the digests was pulsed for 1 h on 30,000 LB1841-EBV-B
cells, which were then cocultured with autologous CTLs 52 (6,000 cells
per well). IFN- production was measured by ELISA after overnight
coculture. The results shown represent the averages and standard devia-
tions of triplicate cultures.
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fied by online electrospray ionization/mass spectrometry.
The kinetics of degradation of the precursor peptide indi-
cated that the overall activity of both proteasome prepara-
tions was similar (Fig. 8 A). The fragments resulting from a
single cleavage at the exact NH2 terminus or at the exact
COOH terminus of antigenic peptide 114AELVHFLLL122
were more abundant after digestion with immunoprotea-
somes (Fig. 8 B and C). The final antigenic peptide was
also present in the digests and was much more abundant af-
ter digestion with immunoproteasomes (Fig. 8 D). In con-
trast, standard proteasomes were more active than immu-
noproteasomes to cleave within the antigenic peptide, after
Leu120 and Phe119 (Fig. 8 E and F). This internal cleavage
could explain why the standard proteasome produces less of
the antigenic peptide.
Discussion
Although a number of antigenic peptides of viral origin
were shown to require the immunoproteasome for their
processing, the nonviral class I antigenic peptides studied so
far are either poorly processed by the immunoproteasome
or processed with the same efficiency by the two protea-
some types (8). We previously showed that an antigenic
peptide derived from ubiquitous protein RU1 and an anti-
genic peptide from melanocytic differentiation protein
Melan-A/MART1 are not processed efficiently by the immu-
noproteasome (4). A tumor-specific antigenic peptide de-
rived from the NY-ESO1 protein was shown by Chen et
al. to be processed equally by the two proteasome types
(27). The MAGE-3.B40 antigen we describe here is the
first example of a tumor-specific antigen that is exclusively
presented by cells carrying immunoproteasomes.
The fact that this is the first tumor antigenic peptide
shown to be more efficiently processed by the immuno-
proteasome could result from the approach that was used to
isolate the CTLs. The classical way to derive antitumor
CTLs is to stimulate lymphocytes from cancer patients with
autologous tumor cells, which usually do not express im-
munoproteasomes. This procedure clearly favors the isola-
tion of CTLs directed against peptides that are processed
efficiently by the standard proteasome. In this study we
have used a different procedure, which is based on the
stimulation of lymphocytes with autologous dendritic cells
infected with a MAGE-3 recombinant virus. Since den-
dritic cells express immunoproteasomes (3), this protocol
should favor the induction of CTLs directed against pep-
tides processed efficiently by the immunoproteasome.
From the mass spectrometric analysis of our peptide di-
gests, it appears that the major reason why the immunopro-
teasome processes the MAGE-3 antigenic peptide much
more efficiently than the standard proteasome is that, as op-
posed to the latter, it does not destroy the antigenic peptide
by cleaving after Phe119 and Leu120. These two residues are
followed by two hydrophobic residues. Interestingly, the
presence of hydrophobic residues immediately downstream
from a cleavage site was recently suggested to impair cleav-
age by the immunoproteasome but not by the standard
proteasome (5). This could explain the difference of effi-
ciency of the two proteasome types to destroy the MAGE-3
antigenic peptide by internal cleavage. The cleavage after
the COOH terminus of the antigenic peptide, on the other
hand, is performed efficiently by the immunoproteasome,
even though it occurs after a leucine like the internal cleav-
age. This further confirms the importance of the context in
determining the efficiency of a given cleavage.
Remarkably, the replacement of only the 5 subunit of
the standard proteasome by 5i is sufficient for efficient
processing of the MAGE-3 antigenic peptide. A simple ex-
planation for the reduced internal cleavage of this peptide
by the immunoproteasome would be that this cleavage is
performed by subunit 5 and not by 5i. The incorpora-
tion of 5i, catalytically active or not, would then be suffi-
cient to prevent the destructive cleavage, as suggested for
an influenza peptide (21). This scenario is not supported by
our finding that the incorporation of a mutated catalytically
inactive 5i subunit does not allow the processing of the
antigenic peptide. Although it does not exclude that 5i
prevents the internal cleavage, this result indicates that the
Figure 8. Mass spectrometric analyses of the fragments observed after
proteasome digestion of a MAGE-3 precursor peptide. The cleavage
products obtained after digestion of the precursor peptide with either
proteasome type were separated by reverse-phase HPLC, identified, and
quantified by online electrospray ionization/mass spectrometry. The ki-
netics shown represent the disappearance of the precursor peptide (A) and
the appearance of the main fragments, including fragments with the
proper NH2 terminus (B), with the proper COOH terminus (C), the fi-
nal antigenic peptide (D), and shorter fragments resulting from internal
cleavages (E and F).
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catalytic activity of 5i is required for the production of the
MAGE-3 antigenic peptide. Our data also differ from those
described for an Hepatitis B virus peptide, whose process-
ing was recently found to require the presence of the three
immunoproteasome subunits, although the catalytic activ-
ity of 5i was not necessary (22).
The fact that the processing of the MAGE-3.B40 antigen
requires only the incorporation of 5i and not the other
subunits of the immunoproteasome is unusual, as a similar
situation has only been observed for two viral antigens (21,
28). 5i is the only immunoproteasome subunit that can be
incorporated into the proteasome in the absence of the two
others, leading to the formation of proteasomes containing
1, 2, and 5i (29). Such proteasomes were isolated re-
cently from rat skeletal muscles (30), and they might be in-
duced by TNF- in human endothelial cells (31, 32). We
also found some 5i in a renal cell carcinoma line in the ab-
sence of IFN- (data not shown). The function of such
proteasomes is unclear, but our results suggest that their
presence could increase or at least modify the repertoire of
antigenic peptides presented at the cell surface.
Given the 5i requirement for the processing of the
MAGE-3 antigen in human melanoma cells, it is surprising
that the antigen can be processed and presented by trans-
fected COS cells, as we observed in Figs. 2 and 3. Although
we have not checked the proteasome type present in COS
cells, these monkey cells most likely contain standard pro-
teasomes as they are not of lymphoid origin and were not
exposed to IFN-. Their capacity to process the MAGE-
3.B40 antigen might result from the high expression levels
achieved after transient transfection of expression vectors
that multiply episomally in COS cells (16). High levels of
expression of the MAGE-3 protein could offset the low
processing efficiency of the standard proteasome and allow
for sufficient amounts of peptide to be presented to the CTL
clone. This would be consistent with the report of Gileadi
et al., showing that the lack of processing of an influenza
epitope by the standard proteasome can be overcome by in-
creasing the turnover of the parental protein (21).
Whereas it is widely accepted that the proteasome is re-
quired for the production of the COOH terminus of
most peptides, there is increasing evidence that the NH2-
terminal cleavage can be performed by other peptidases,
the nature of which is under investigation (33, 34). Such
NH2-terminal trimming by distinct peptidases is probably
not required for the processing of the MAGE-3 antigenic
peptide, as we clearly detected fragments with the proper
NH2 terminus within the digests obtained with immuno-
proteasomes.
The new MAGE-3 antigenic peptide is presented by
HLA-B*4001, a class I molecule expressed by 8% of Cau-
casians and 10% of Asians (35). Interestingly, this new anti-
genic peptide is not only encoded by MAGE-3 but also by
MAGE-12. These two genes are expressed in 76 and 62%
of metastatic melanomas, respectively. The fact that the
same peptide is encoded by two distinct genes should re-
duce the probability of emergence of tumor variants having
lost expression of this antigen.
Vaccination strategies against cancer should take into ac-
count the differential processing of tumor antigens by the
two proteasome types. Given the high expression of im-
munoproteasomes in mature dendritic cells, the MAGE-3
peptide described here should be efficiently produced by
dendritic cells and, consequently, strong CTL responses
should be obtained. Tumor cells, however, need to be ex-
posed to IFN- in order to express the immunoproteasome
and present this antigen. CTLs against this antigen should
therefore be useful only once an immune response has been
initiated at the tumor site. Optimal vaccination strategies
could combine the use of peptides more efficiently pro-
duced by the standard proteasome with peptides more effi-
ciently produced by the immunoproteasome.
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